Disclosed herein are new compositions comprising (1) an antibacterial component comprising (a) a complex comprising (i) an active pharmaceutical ingredient (API) wherein the active pharmaceutical ingredient is tobramycin, a similar compound, or a derivative of either thereof and (ii) a complexing agent, or (b) a derivative of tobramycin or a similar compound comprising one or more conjugates/derivatizing groups, wherein the complexing agent or conjugate(s) cause a detectable increase in API permeation of corneal cells, retention in corneal cells, or both, as compared to the non-complexed or non-derivatized API, and (2) an effective amount of an anti-inflammatory agent, such as dexamethasone or another dexamethasone compound. This disclosure also describes new methods of using such compositions, producing such compositions, and the like.

A medical material uses a nickel-titanium alloy wherein a polyelectrolyte has a reduced thickness while a sufficient amount of an antithrombogenic compound for production of a therapeutic effect is supported. The medical material in which a porous surface is formed on a nickel-titanium alloy to allow infiltration of a polyelectrolyte into the pores, to thereby reduce the thickness of the polyelectrolyte exposed on the surface of the nickel-titanium alloy while allowing supporting of a sufficient amount of an antithrombogenic compound due to contribution of the polyelectrolyte infiltrate.

This invention discloses the creation of a novel single ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a group of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery and/or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties. The stereoisomer peptides carried by the polymer are delivered to cells or tissues to inhibit, suppress, block, antagonize or disrupt, simultaneously and independently, the functional domain of different disease causing proteins. Therefore the compounds are novel therapeutics for the treatment of abnormal angiogenesis and inflammation which are the hall mark of most human diseases including but not limited to all cancers, metastasis, eye retinopathies, cardiovascular, brain, and neurodegenerative disorders, diabetes, and diseases caused by infectious microorganisms including virus, bacteria, fungi, and parasites.

The present invention relates to HPMA-CBz copolymers and methods for treating certain diseases comprising administering the copolymers to a subject in need thereof.

The present invention relates to HPMA-CBz copolymers and methods for treating certain diseases comprising administering the copolymers to a subject in need thereof.

Copolymers polymerized from at least one or more cinchona alkaloid containing compounds; and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Method of forming a copolymer-genetic component complex that includes a genetic component and a copolymer where the copolymer includes one or more cinchona alkaloid containing compounds and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Methods of delivering a genetic component to a cell.

Copolymers polymerized from at least one or more cinchona alkaloid containing compounds; and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Method of forming a copolymer-genetic component complex that includes a genetic component and a copolymer where the copolymer includes one or more cinchona alkaloid containing compounds and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Methods of delivering a genetic component to a cell.

In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.